Codex BioSolutions

Codex Therapeutics, Inc. is an early stage drug development company with its offices and laboratories in Parsippany, New Jersey. Codex is developing a topical gel from human HSP90a protein to substantially reverse chronic wound healing times. The company is currently focusing on the preclinical development of its leading drug candidate, CT-115, which has shown potent efficacy in the FDA's assessment criteria of 100% Wound Healing Incidence and Accelerated Healing Time in mice and pigs. The drug is aimed to treat diabetic, pressure and venous ulcers for which there remains significant unmet clinical need and for which the NIH estimates annual care costs of $25B annually. The advanced wound care market Codex will serve includes chronic wounds, acute wounds, surgical wounds, burns and other potentially slow-healing wounds. GIA, Vision Care and others estimate the advanced wound care products market to exceed $15.6B globally. The Biologics sub-segment (where Codex's topical CT-115 will compete) is estimated at $5.6-6.7 Billion annually. The Biologics are expected to be the fastest growing segment with annual growth rates estimated at as much as 15% and higher per year. Jean Ann Berthold, Codex's Chief Executive Officer, is an experienced entrepreneur with award winning performance in business planning, marketing strategy and new technology deployment for her previous investor-funded high tech venture. Co-founder and Chief Technical Officer, Dr. Wenshan Hao , received his PhD from USC and completed his postdoc training at Caltech. He served as Sr. Scientist at Wyeth, co-founded U-Pharm Laboratories, and collaborated with Co-founder and Business Development Director, Dr. Jimmy Lu on $700K of awarded SBIR grants from the NIH and the US Army/DOD. Dr. Jimmy Lu earned his Ph.D. from Georgetown, completed his postdoc training at the NIH, served as a Senior Research Scientist at BD Biosciences (2001-2009), and then founded his own contract R&D firm, Codex BioSolutions in 2009. The Company is currently raising investment capital to fund the development and commercialization of CT-115 with assistance from its partners through preclinical stages and human clinical trials to our FDA approval, product launch and marketing of our product globally. Additional advanced wound care biologics are under consideration for future development by Codex.